Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. is the innovation accelerator arm of Leonhardt Ventures LLC. The Leonhardt team has been developing breakthrough medtech innovations since the 1980s with PolyCath in 1988, TALENT stent graft, StentValve, RadiCath, ProCell, DeltaVein, BioPace, Valvublator and PENSIL in the 1990s. Leonhardt led a team in Melbourne, Australia that completed the landmark first aortic aneurysm repair with percutaneous delivery working with Dr. Ken Thomson at the Royal Melbourne Hospital. Their stent graft has world leading market share today for non-surgical repair of aortic aneurysms as part of Medtronic. MyoCell, MyoCath, AortaCell, BioLeonhardt, Vascustim (formerly MyoStim Peripheral) in the 2000’s. In early 2001 Leonhardt led a team that completed the historic first muscle stem cell repair of a a human heart without surgery working with Dr. Patrick Serruys and Dr. Doris Taylor in The Netherlands. Leonhardt’s Launchpads was launched in 2008 in Santa Rosa, California as a biotech medtech incubator and Cal-X Stars Business Accelerator, Inc. in Santa Monica in 2012 as an innovation accelerator. The two merged in late 2016 and now focus on leveraging the Leonhardt core IP in bioelectrics, biologics and endovascualr delivery systems with over 38 breakthrough applications in development https://leonhardtventures.com/development-pipeline/.
Cal-X Stars Business Accelerator, Inc. spun out Cal-Impact in 2018 www.cal-impact.com forming a separate innovation accelerator focused on social good impact innovations. The team has over 600 patent claims issued, pending, in process, optioned or licensed for organ regeneration and recovery – https://patents.justia.com/inventor/howard-j-leonhardt. Over 600,000 patients have been treated with Leonhardt inventions to date.
Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. focuses on applying the Leonhardt Ventures LLC core IP in bioelectrics, biologics and endovascular delivery systems to organ regeneration and healing forming a separate innovation asset, Licensable Technology Platform, or startup for each organ or purpose specific application.